New data from several studies of compounds discovered by HUTCHMED (00013.HK) +0.250 (+1.188%) Short selling $25.11M; Ratio 10.511% including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place on 30 May-3 June 2025 in Chicago, USA, according to HUTCHMED's announcement.Results from the SACHI China Phase III study of savolitinib in combination with osimertinib in patients with locally advanced or metastic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET amplification after disease progression on EGFR inhibitor therapy will be presented at a late breaking oral presentation. Related NewsG Sachs Lifts 2026-27 HK Property Price Forecasts, Keeps Rating Buy on SHK PPT/ CK ASSETSACHI had met the pre-defined primary endpoint of progression-free survival (PFS) in a planned interim analysis. SACHI data supports the New Drug Application (NDA) for this oral-only treatment, which has been accepted and granted priority review in China. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-23 16:25.)